Please ensure Javascript is enabled for purposes of website accessibility

Did Constellation Brands Waste $4 Billion on Canopy Growth?

By Rich Duprey - Feb 3, 2020 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The marijuana producer has been more anchor than sail for the alcoholic beverages distributor.

Constellation Brands' (STZ -0.14%) $190 million investment in Canopy Growth (CGC -5.96%) in 2017 for a 10% stake in the marijuana producer altered the landscape for the legal weed industry. Because it was the first major company to put money into pot, it bestowed much-needed legitimacy on the industry.

Yet as Canopy Growth stumbles over yet another seemingly unforced error, investors may begin questioning whether Constellation wasted the $4 billion it eventually poured into the pot producer, and so far, the record isn't very encouraging.

Beverages with marijuana leaves.

Image source: Getty Images.

Lurching forward

Canopy Growth's latest snafu is its delay in introducing its so-called Cannabis 2.0 lineup of marijuana-infused beverages. Instead of the January 2020 launch date it originally promised, Canopy pushed it back to some indefinite time in the future to give it the chance to scale up its production facility.

"In order to deliver products that meet our customer's high standards we are electing to revise the launch date while we work through the final details," CEO David Klein said in a statement.

Considering Constellation is one of the premier beer and wine distributors in the U.S. and its investment in Canopy was predicated not on how much dried cannabis flower or leaf the pot grower could sell but on the drinks it could produce, being ready to hit the ground running when it got the green light should have been a priority.

Canopy submitted its application for a beverage facility last June, and Canada's regulations for Cannabis 2.0 went into effect in October. Canada Health issued Canopy a license in November and the marijuana producer announced the following month it was launching its beverages in January. And then it said it wasn't.

While Canopy says the delay shouldn't have a material impact on its revenue this year, suggesting it may not be too big of a deal over the long term, it is ceding the early ground to other companies that are prepared to move forward with cannabis-infused beverages of their own.  For example, Truss Beverages, the joint venture of HEXO and Molson Coors, and Fluent Beverage, the partnership between Tilray and Anheuser-Busch, also have a full lineup of drinks ready to go.

Overpromise, underdeliver

If this were Canopy's only blunder, it would be easy to excuse, but the marijuana producer seems to regularly trip itself up.

Last quarter Canopy reported that sales tumbled 15% year over year to CA$76.6 million because it misjudged demand in the cannabis oils market and had to recognize CA$32.7 million in adjustments due to a large number of returns.

It has also overpaid for acquisitions, and it operated with seemingly little oversight from the board of directors, who allowed former co-CEO Bruce Linton to freely distribute the company's cash hoard so that its balance has been nearly halved to CA$2.7 billion. While Linton was eventually ousted and a Constellation executive installed in his place, Canopy remains a loss-generating operation with no end in sight.

The recent placement of another Constellation executive on Canopy's board implies the beverage company might want a few more adults in the room to stop the hemorrhaging, but it also suggests a good part of Canopy's future will be in beverages.

A glass half empty

That's good if cannabis-infused drinks are as big as some hope, but like oils and dried flower and leaf demand, this may be a more underwhelming figure than expected. Although some analysts see them growing to $1.4 billion by 2023, where they are legal to buy in the U.S. they haven't moved the needle, accounting for about 6% of the entire edibles market. There may be a market for them, but demand may not be so great after all.

It's too early to say that Constellation has wasted its money on Canopy Growth. After all, it may simply have been a defensive move to be part of an industry that's seen as potentially undermining alcohol sales.

Yet it's also apparent that whatever benefit Constellation hoped it would derive from its investment in marijuana won't be generating any positive returns for some time to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
STZ
$234.50 (-0.14%) $0.33
Canopy Growth Stock Quote
Canopy Growth
CGC
$5.52 (-5.96%) $0.35
Anheuser-Busch InBev SA/NV Stock Quote
Anheuser-Busch InBev SA/NV
BUD
$54.27 (0.39%) $0.21
Molson Coors Beverage Company Stock Quote
Molson Coors Beverage Company
TAP
$51.23 (0.89%) $0.45
Tilray Stock Quote
Tilray
TLRY
HEXO Stock Quote
HEXO
HEXO
$0.28 (-5.11%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.